Interviews

Emma Searle, PhD, discusses the dosing approach of the MajestTEC-2 trial (NCT04722146) and sequencing teclistamab (Tecvayli) in patients with multiple myeloma.

In an interview with Targeted Oncology, Mitchell Smith, MD, PhD, discussed what the findings from the ECOG-ACRIN E1411 trial in patients with mantle cell lymphoma means for the future of the space, and where research is heading.

Ashish Saxena, MD, PhD, discusses the standard-of-care regimens use to treat patients with small cell lung cancer at every stage.

Marc S. Ernstoff, MD, discusses why physicians would treat metastatic melanoma with immunotherapy prior to small molecule inhibitors in most cases.

In an interview with Targeted Oncology, Ken Kato, MD, PhD, discussed background and findings from the phase 3 CheckMate 648 trial among patients with esophageal squamous cell carcinoma.

Mark A. Socinski, MD, discusses types of EGFR mutations in non–small cell lung cancer and the treatments that target these mutations.

Pierre Gholam, MD, discusses his thoughts on a phase 3 trial which evaluated camrelizumab plus rivoceranib vs sorafenib in the first-line for patients with unresectable hepatocellular carcinoma.

In an interview with Targeted Oncology, John Nakayama, MD discussed 2 recently reported, practice-changing studies in endometrial cancer, and where the field is heading.

Yuri E. Nikiforov, MD, PhD, discusses the approach to treating noninvasive follicular thyroid neoplasm with papillary-like nuclear features, which is now classified distinctly from thyroid cancers.

Emma Searle, discusses safety results of the MajestTEC-2 trial which combined teclistamab with daratumumab and lenalidomide in patients with multiple myeloma.

John T. Nauseef, MD, PhD, discusses an investigational prostate-specific membrane antigen targeted therapy for the treatment of metastatic castration-resistant prostate cancer.

In an interview, Samer A. Srour, MD, MS, reviewed data from the dose-expansion phase of an ongoing phase 1 trial of Orca-Q in the haploidentical stem cell transplant setting for patients with high-risk hematologic malignancies.

In an interview with Targeted Oncology, Jones T. Nauseef, MD, PhD, discussed the investigational PSMA targeted therapy, 225Ac-J591, and results from a phase 1 study.

In an interview with Targeted Oncology, Mitchell E. Horwitz, MD, discussed the FDA approval of omidubicel for the treatment of patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant.

John P. Diaz, MD, explains the importance of the topics to be discusses at the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.

In an interview, Ashish Saxena, MD, discussed the benefit of radiation for the treatment of small cell lung cancer, combining radiation with immune checkpoint blockade treatments, and the next steps for the space.

John P. Diaz, MD, provides an overview of the topics to be discusses during the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.

Yousef Zakharia, MD, discusses the COSMIC-313 study and its implications to date.

In an interview with Targeted Oncology, Ajay Nooka, MD, discussed findings from the phase 3 KarMMa-3 trial and the use of ide-cel for the treatment of patients with relapsed/refractory multiple myeloma.

Samer A. Srour, MD, discusses Orca Q graft and how it’s revolutionized haploidentical allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

In an interview with Targeted Oncology, Olumide B. Gbolahan, MBBS, MSc, commented on studies that support the use of ctDNA to guide treatment decisions in the adjuvant setting for patients with colorectal cancer.

Roby Thomas, MD, provides ideas for oncologists to consider while multiple chemotherapy drug are on shortage in the United States.

In an interview with Targeted Oncology, Bruno Bockorny, MD, discussed background and key takeaways from the phase 1 C-800 study.

Looking at the results of the BIONIKK trial, Yann-Alexandre Vano, MD, discusses the importance of having biomarkers drive treatment decisions in patients with metastatic renal cell carcinoma.

According to Hagop M. Kantarjian, MD, there are options for limited oncology drug shortages that require multi-sector involvement.

In an interview with Targeted Oncology, Nitika Sharma, MD, discussed frontline treatment options for small cell lung cancer and data supporting their use. Sharma also discussed ongoing clinical trials that may bring new therapies in the near future.

While results of the PALOMA-2 study did not show a survival benefit for the overall population on the combination of palbociclib and letrozole but did show an overall survival benefit in Black patients on the combination therapy.

In an interview with Targeted Oncology, Bridget Koontz, MD, discussed burnout and its importance in experts treating patients with cancer.

Mitchell Smith, MD, PhD, discusses how the updated results of the phase 2 ECOG-ACRIN E1411 trial of patients with previously untreated mantle cell lymphoma can be interpreted in context of data supporting the use of the Bruton’s tyrosine kinase inhibitor ibrutinib in this setting.

Tycel Phillips, MD, discusses the agents available for the second-line treatment of diffuse large B-cell lymphoma, and the utility of chimeric antigen receptor T-cell therapy.